A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: Effects on dermal cellularity and cutaneous tumour necrosis factor-alpha

Veterinary Dermatology

Volumn 14, Issue 1, 2003, Pages 37-46

  Olivry, Thierry ^a   Dunston, Stanley M ^a   Rivierre, Christine ^a   Jackson, Hilary A ^a   Murphy, K Marcy ^a   Peters, Erin ^a   Dean, Gregg A ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Allergy; Atopic dermatitis; Atopy; Canine; Misoprostol; Randomized controlled trial; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE; MESSENGER RNA; MISOPROSTOL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; DERMATOLOGICAL AGENT;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ARTICLE; ATOPIC DERMATITIS; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOFLUORESCENCE; MALE; NONHUMAN; PRURITUS; SCORING SYSTEM; SKIN CELL; TREATMENT OUTCOME; ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANIMALIA; CANIS FAMILIARIS;

ADMINISTRATION, ORAL; ANIMALS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MALE; MISOPROSTOL; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037310297     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3164.2003.00323.x     Document Type: Article

References (32)

1. Olivry, T., Sousa, C.A. The ACVD task force on canine atopic dermatitis (XIX). General principles of therapy. Veterinary Immunology and Immunopathology 2001; 81: 311-16.
2. Olivry, T., Sousa, C.A. The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy. Veterinary Immunology and Immunopathology 2001; 81: 317-22.
3. Deboer, D.J., Griffin, C.E. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Veterinary Immunology and Immunopathology 2001; 81: 323-30.
4. Marsella, R., Olivry, T. The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy. Veterinary Immunology and Immunopathology 2001; 81: 331-45.
5. Olivry, T., Marsella, R., Hillier, A. The ACVD task force on canine atopic dermatitis (XXIII): are essential fatty acids effective? Veterinary Immunology and Immunopathology 2001; 81: 347-62.
6. Olivry, T., Guaguère, E., Héripret, D. Treatment of canine atopic dermatitis with the prostaglandin E1 analog misoprostol: an open study. Journal of Dermatological Treatment 1997; 8: 243-7.
7. Davies, N.M., Longstreth, J., Jamali, F. Misoprostol therapeutics revisited. Pharmacotherapy 2001; 21: 60-73.
8. Leandro, G., Pilotto, A., Franceschi, M. et al. Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Digestive Diseases and Sciences 2001; 46: 1924-36.
9. Kahn, J.G., Becker, B.J., MacIsaa, L. et al. The efficacy of medical abortion: a meta-analysis. Contraception 2000; 61: 29-40.
10. Smith, W.G., Thompson, J.M., Kowalski, D.L. et al. Inhaled misoprostol blocks guinea pig antigen-induced bronchoconstriction and airway inflammation. American Journal of Respiratory and Critical Care Medicine 1996; 154: 295-9.
11. Wasiak, W., Szmidt, M. A six-week double-blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma. Thorax 1999; 54: 900-4.
12. Alam, R., DeJarnatt, A., Stafford, S. et al. Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog -Results of a double-blind, placebo-controlled randomized study. American Review of Respiratory Diseases 1993; 148: 1066-70.
13. Alam, R., DeJarnatt, A., Stafford, S. et al. Misoprostol inhibits the cutaneous late-phase allergic response to antigens. Results of a double-blind placebo-controlled randomized study and an investigation into the mechanism of action. American Journal of Therapeutics 1995; 2: 749-54.
14. Shah, P.M., Pearce, F.L. Effect of misoprostol on histamine secretion from isolated rat and human mast cells and basophils. American Journal of Therapeutics 1995; 2: 768-71.
15. Babakhin, A.A., Nolte, H., DuBuske, L.M. Effect of misoprostol on the secretion of histamine from basophils of whole blood. Annals of Allergy Asthma and Immunology 2000; 84: 361-5.
16. Widomski, D.L., Walsh, R.E., Baron, D.A. et al. Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes. Agents Action 1991; 34: 30-1.
17. Widomski, D., Fretland, D.J., Gasiecki, A.F. et al. The prostaglandin analogs, misoprostol and SC-46275, potently inhibit cytokine release from activated human monocytes. Immunopharmacology and Immunotoxicology 1997; 19: 165-74.
18. Vinogradov, A.I., Vinogradova, N.A. Study of prostaglandin E2 antimediator properties and therapeutic efficacy in children suffering from atopic dermatitis [in Russian]. Vestnik Dermatologii I Venerologii 1993; N4: 24-8.
19. Willemse, T. Atopic skin disease: a review and a reconsideration of diagnostic criteria. Journal of Small Animal Practice 1986; 27: 771-8.
20. Olivry, T., Rivierre, C., Jackson, H.A. et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolonecontrolled trial. Veterinary Dermatology 2002; 13: 77-87.
21. Olivry, T, Steffan, J., Fisch, R.D. et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association 2002; 221: 370-7.
22. Rivierre, C., Dunston, S.M., Olivry, T. Effects of a 1 per cent hydrocortisone conditioner on the prevention of immediate and late phase reactions in canine skin. Veterinary' Record 2000; 147: 739-42.
23. Olivry, T., Dean, G.A., Tompkins, M.B. et al. Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs. Experimental Dermatology 1999; 8: 204-11.
24. Olivry, T., Murphy, K.M., Dunston, S.M. et al. Characterization of the inflammatory infiltrate during IgE-mediated late-phase reactions in the skin of normal and atopic dogs. Veterinary Dermatology 2001; 12: 49-58.
25. Hillier, A., Cole, L.K., Kwochka, K.W. et al. Late-phase reactions to intradermal testing with Dermatophagoides farinae in healthy dogs and dogs with house dust mite-induced atopic dermatitis. American Journal of Veterinary Research 2002; 63: 69-73.
26. Mahatma, M., Agrawal, N., Dajani, E.Z. et al. Misoprostol, but not antacid, prevents endotoxin-induced gastric mucosal injury: role of tumor necrosis factor alpha. Digestive Diseases and Sciences 1991; 36: 1562-8.
27. Hogaboam, C.M., Bissonnette, E.Y., Chin, B.C. et al. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology 1993; 104: 122-9.
28. Ishikawa, O., Kubota, Y., Miyachi, Y. Prostaglandin E1 suppresses tumor necrosis factor-alpha and interleukin-10 production by lipopolysaccharides-stimulated mononuclear cells. European Journal of Pharmacology 1998; 344: 95-8.
29. Marsella, R., Nicklin, C.F. Double-blinded cross-over study on the efficacy of pentoxifylline for canine atopy. Veterinary Dermatology 2000; 11: 255-60.
30. Ferrer, L., Alberola, J., Queralt, M. et al. Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis. Veterinary Record 1999; 145: 191-4.
31. Ewert, G., Daems, T. Treatment of canine atopic dermatitis by a fatty acid copolymer: comparative double blind study. Pratique Medicale et Chirurgicale de L Animal de Compagnie 2001; 36: 401-8.
32. Hill, P.B., Hillier, A., Olivry, T. The ACVD task force on canine atopic dermatitis (VI). IgE-induced immediate and late-phase reactions, two inflammatory sequences at sites of intradermal allergen injections. Veterinary Immunology and Immunopathology 2001; 81: 199-204.